Member Info for Mafuta

We see this latest development as a mild setback for Sareum given that GSK’s support could have accelerated development activity on the drug, triggering a $0.55m payment to Sareum from first patient dosing in a new clinical trial. However, it does provide Sareum and partner CPF with an opportunity to actively assess future development plans for SRA737, leveraging the positive clinical data.

https://mailers.edisongroup.com/e3t/Ctc/OP+113/cJYS804/VVWHsD4-2GkgW5cvfy027H-vJVGwS3m4R2LVxN15bQXc3q3nJV1-WJV7CgV9wMsJ177M3HQwW2Gc2-x4bjHlxV_mbrc4RQ1KVW1Vn3rQ1CnqlwW7VYK7275VLqHW3CFn3W3Ztp9BW4S1X1N1VmrVDW2_BPzj4hc657W39MydH7yB8HcW6yfmnv62kCtkW4BVzh43yFLgkN86jD722hv9dW7Llzdm40DpSWW6tpT2x28Br4wW3ht7B85cJBSyW6njwVV4H6F5qW60vBqM27CYkKW46JJnr4qWxCLW5xfL-D7CqHL9W6CTlf41QwwwwW2CQsz75g70PxW89NSHj8bzX1ZVyxKMZ2h--rzW8M0Wnf3vtLZt32L51

Calling someone you don't know dishonest really sums you up ... I don't wish you or anyone else any harm, I was just expressing an opinion ... Which I guess is the raison d'etre for chat rooms? ... Sorry to say I won't be missing your inessant moaning ... I hope you do well elsewhere ... and have a restful night ... you'll feel better in the morning once you've sold out ...LH&K Mafuta

Over the next few weeks is who will take up 737 and how much will they be willing to pay for it ... could SAR afford a bigger slice of the cake ... Could be quite telling LH&K Mafuta

Utah I was being polite ... However when you do sell up and go hopefully we won't have to listen to your negative drivel ... Best to sell at market open ... Put your sell in and when you wake up tomorrow you'll be a liberated person ... LH&K Mafuta

Utah it's your money ... Do what you want

I have the feeling the news has been factored in over the past couple of days

Cambridge, UK, 12 October 2022 - Sareum Holdings plc (AIM: SAR), a clinical stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that it has been informed by Sierra Oncology, Inc. ("Sierra") (a subsidiary of GSK plc ("GSK") that it intends to return the rights for SRA737 to the CRT Pioneer Fund LP ("CPF").

Now that's a bit of a curve ball

HBD

It's this quote that stood out for me:

"why should large pharmaceutical companies bother with the time and expense of developing their own drugs when they can buy a partially-developed drug for less than the cost (and much less risk) than developing one themselves?"

Hi HBD

A bit like an expectant mother at the end of her pregnancy ... She knows the baby is coming but not the time and date ... not quite sure why SAR have not announced the CTA approval but guess there are "compelling" reasons

A good week ... wonder what next week will bring? LH&K Mafuta

Great to see the price strengthening ... Keep it up

That's a fair amount of flesh he has put in the game ... Well done Jeremy

https://www.fiercebiotech.com/biotech/spying-devilish-deal-astrazeneca-pays-666-premium-buy-genomic-medicine-biotech

And I wouldn't be surprised if one of our HNWI exercises their warrents in the not too distant future

Totally agree RMM the recent increases are hardly demand driven ... so the MMs are doing what they do best ... Market Manipulation ... but who cares as long as its in the right direction ... unless of course you're short ... LH&K Mafuta

And it's more than 12 inches ... I think news will surface pretty soon ... LH&K Mafuta

HBD .. Thanks for all your hard work ... Just goes to show that there is a possible income stream ... Although price sensitive ... LH&K Mafuta

Excellent research HBD ... As we see the price increase it will be interesting to see how our HNWI take up their options ... Thank you for this information LH&K Mafuta

Thanks HBD I take it that at these points there is a possibility of more cash inflow providing the HNWI exercise their options? Would that cover funding for the next stage of trials?